Drugs /

apoptosis inducer bzl101

Back to Drugs List

Overview

NCI Definition [1]:
An orally active aqueous extract derived from the plant Scutellaria barbata with potential antineoplastic activity. Sparing normal cells, apoptosis inducer BZL101 specifically facilitates translocation of the protein apoptosis-inducing factor (AIF) from the mitochondrial membrane into the nucleus in tumor cells, thereby causing tumor cell-specific chromatin condensation and DNA degradation followed by the induction of caspase-independent apoptosis. AIF is both a mitochondrial intermembrane flavoprotein with oxidoreductase activity and a caspase-independent death effector that, similar to cytochrome c, is released from mitochondria early in the apoptotic process.

Clinical Trials

View Clinical Trials for apoptosis inducer bzl101

Apoptosis inducer bzl101 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating apoptosis inducer bzl101, 1 is phase 2 (1 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for apoptosis inducer bzl101 clinical trials.

Breast carcinoma is the most common disease being investigated in apoptosis inducer bzl101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Apoptosis Inducer Bzl101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating apoptosis inducer bzl101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
apoptosis inducer bzl101, bzl101
NCIT ID [1]:
C69134

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.